Needham & Company analyst, Mike Matson, reiterated his Buy rating on shares of Hologic (NASDAQ: HOLX) but cut his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE